# Meta−analysis of right versus left (studies with wild type patients) stratified by type of treatment

| Author | logHR | logHR (SE) | 95% CI | Hazard ratio | HR | Weight (fixed) | Weight (random) |
|---|---|---|---|---|---|---|---|
| **Subgroup Treatment = Chemotherapy + anti−EGFR** | | | | | | | |
| 20050181 | 0.70 | 0.2261 | [1.29; 3.13] | | 2.01 | 4.0% | 4.2% |
| CRYSTAL | 0.66 | 0.2245 | [1.24; 3.00] | | 1.93 | 4.0% | 4.3% |
| FIRE−3 | 1.04 | 0.2156 | [1.86; 4.33] | | 2.84 | 4.4% | 4.5% |
| CALGB 80405 | 0.60 | 0.1788 | [1.28; 2.58] | | 1.82 | 6.4% | 5.5% |
| PRIME | 0.46 | 0.2235 | [1.02; 2.45] | | 1.58 | 4.1% | 4.3% |
| PEAK | 0.99 | 0.3641 | [1.31; 5.47] | | 2.68 | 1.5% | 2.1% |
| AIO KRK0104 | 0.87 | 0.2519 | [1.45; 3.90] | | 2.38 | 3.2% | 3.7% |
| JACCRO CC−05/06 | 1.27 | 0.3173 | [1.92; 6.65] | | 3.57 | 2.0% | 2.6% |
| MACRO−2+PLANET | 0.69 | 0.2174 | [1.31; 3.06] | | 2.00 | 4.3% | 4.4% |
| Fiala | 0.83 | 0.2316 | [1.45; 3.61] | | 2.29 | 3.8% | 4.1% |
| Uhlyarik | 0.70 | 0.2077 | [1.34; 3.02] | | 2.01 | 4.7% | 4.7% |
| CAIRO−3 | 0.11 | 0.2684 | [0.66; 1.90] | | 1.12 | 2.8% | 3.3% |
| Fixed effect model | | | [1.79; 2.33] | | 2.04 | 45.3% | −− |
| Random effects model | | | [1.73; 2.42] | | 2.05 | −− | 47.6% |
| Test for effect in subgroup (fixed effect): $z = 10.64$ ($p < 0.01$) | | | | | | | |
| Test for effect in subgroup (random effects): $t_{11} = 9.40$ ($p < 0.01$) | | | | | | | |
| | | | | | | | |
| **Subgroup Treatment = Chemotherapy + anti−VEGF** | | | | | | | |
| FIRE−3 | 0.39 | 0.1914 | [1.02; 2.15] | | 1.48 | 5.6% | 5.1% |
| CALGB 80405 | 0.13 | 0.1784 | [0.80; 1.62] | | 1.14 | 6.4% | 5.5% |
| PEAK | 1.05 | 0.3644 | [1.40; 5.84] | | 2.86 | 1.5% | 2.1% |
| TRIBE | 0.54 | 0.2596 | [1.03; 2.86] | | 1.72 | 3.0% | 3.5% |
| AIO KRK0207 | 0.44 | 0.1987 | [1.06; 2.30] | | 1.56 | 5.2% | 4.9% |
| Fiala | 0.54 | 0.2872 | [0.97; 3.00] | | 1.71 | 2.5% | 3.0% |
| Fixed effect model | | | [1.26; 1.80] | | 1.51 | 24.2% | −− |
| Random effects model | | | [1.17; 2.00] | | 1.53 | −− | 24.2% |
| Test for effect in subgroup (fixed effect): $z = 4.46$ ($p < 0.01$) | | | | | | | |
| Test for effect in subgroup (random effects): $t_{11} = 4.09$ ($p < 0.01$) | | | | | | | |
| | | | | | | | |
| **Subgroup Treatment = Chemotherapy alone** | | | | | | | |
| 20050181 | 0.41 | 0.2305 | [0.96; 2.37] | | 1.51 | 3.8% | 4.1% |
| CRYSTAL | 0.30 | 0.1915 | [0.93; 1.96] | | 1.35 | 5.6% | 5.1% |
| PRIME | 0.24 | 0.1868 | [0.88; 1.83] | | 1.27 | 5.8% | 5.3% |
| Fixed effect model | | | [1.08; 1.70] | | 1.36 | 15.2% | −− |
| Random effects model | | | [1.10; 1.67] | | 1.36 | −− | 14.5% |
| Test for effect in subgroup (fixed effect): $z = 2.64$ ($p < 0.01$) | | | | | | | |
| Test for effect in subgroup (random effects): $t_{11} = 6.38$ ($p = 0.02$) | | | | | | | |
| | | | | | | | |
| **Subgroup Treatment = Mixed therapies** | | | | | | | |
| OPTIMOX3 DREAM | 0.42 | 0.1650 | [1.10; 2.10] | | 1.52 | 7.5% | 6.0% |
| Demurtas | 1.04 | 0.3536 | [1.42; 5.66] | | 2.83 | 1.6% | 2.2% |
| Kamran | 0.71 | 0.1821 | [1.43; 2.91] | | 2.04 | 6.1% | 5.4% |
| Fixed effect model | | | [1.46; 2.29] | | 1.83 | 15.3% | −− |
| Random effects model | | | [0.96; 3.71] | | 1.89 | −− | 13.6% |
| Test for effect in subgroup (fixed effect): $z = 5.22$ ($p < 0.01$) | | | | | | | |
| Test for effect in subgroup (random effects): $t_{11} = 4.04$ ($p = 0.06$) | | | | | | | |
| | | | | | | | |
| **Fixed effect model** | | | [1.60; 1.91] | | 1.75 | 100.0% | −− |
| **Random effects model** | | | [1.59; 2.02] | | 1.79 | −− | 100.0% |

0.2  0.5  1  2  5